Get the app
US › Healthcare

Rocket Pharmaceuticals Inc (RCKT)

US · Healthcare · Biotechnology

$2.18-7.63%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$123.2M
EPS
$-0.15
EPS estimate
$0.28

EPS came in at -0.15 against a street estimate of 0.28 — a miss of 153.6%.

Key statistics

Market cap
$259.1M
Forward P/E
0.0
P/B
0.90
Book value
$3.37
EPS (TTM)
$-0.16
52-week high
$5.45
52-week low
$2.18
50-day MA
$3.24
200-day MA
$3.53
Beta
0.50

Analyst view

Analysts rate Rocket Pharmaceuticals Inc a buy (7 buy, 5 hold, 2 sell out of 14) with an average price target of $8.85.

Shareholding

Insiders
3.18%
Institutions
91.79%

Largest institutional holders

FundStake
RTW INVESTMENTS, LLC16.11%
BlackRock Inc9.04%
Vanguard Portfolio Management, LLC5.29%
Citigroup Inc4.43%
Marshall Wace Asset Management Ltd3.67%
Millennium Management LLC3.64%
Newtyn Management LLC3.64%
Maverick Capital Ltd3.57%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Rocket Pharmaceuticals Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.